Abstract
Purpose: The purpose of this study was to address the question of “superiority of R-CHOP versus CHOP”, with addition of Rituximab to CHOP, regarding survival of patients suffering from DLBCL. Patients and methods: A cohort retrospective design was used to conduct this study in a tertiary care hospital. A total of 100 patients (50 in each group) were randomly selected. The primary and secondary end points were EFS, OS, PFS and DFS. Kaplan Meier survival curve analysis (log rank, Breslow and Tarone ware tests) was employed to compare probability of survival for the two groups (CHOP/ R-CHOP). Results: The mean primary and secondary clinical indicators were estimated for each group (EFS, 1.7; 3.09 with a p value P=0.02), (OS, 0.60; 0.43 with a p value P=0.40), (PFS, 1.73; 3.57 with a p value P=0.002), (DFS, 0.02; 0.48 with a p value of P=0.00). Conclusion:The results for differences in clinical response were statistically significant in favor of the R-CHOP group.